Equity
€3,892 ▼ 66.4%
Dr. Morgane Daix paid out €48,600 in dividends. That is 119% of the 2025 profit.
Dr. Morgane Daix
Lifetime
5 annual accounts with figures on one time axispeak €79,887 (2023)
€47,643▼ 38.6%
peak €60,408 (2023)
€40,907▼ 27.2%
peak €29,978 (2022)
€3,892▼ 66.4%
€56,779▼ 64.4%
Board1 name since 2021
1 directorMorgane Maguy Roger DAIX
Documentsfilings and deeds
25-06-202636 days before the deadline
2025micro format
Gross margin from €77,558 to €47,643Result from €56,198 to €40,907Registered office moved from Liège to Neufchâteau 29-04Dividend €48,600Equity from €11,584 to €3,892Debts from €159,292 to €56,779
Key points
from the 2025 annual accountsDebts
€56,779 94% of the balance sheet
Suppliers 4%Taxes and wages 8%Other 88%
Of this, €56,148 falls due within a year.
Position in the sector
€3,892
Less equity than 92% of companies in human health. Sector median €124,598 · 20,751 companies.
Checked score
91
Excellent
Financially stronger than 30% of micro companies in human health (NACE 86)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: < 0.1% across 24,179 companies (NACE 86, micro).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: < 0.1%
01-2025: < 0.1%● unchanged vs 12-2024
02-2025: < 0.1%● unchanged vs 01-2025lowest value
03-2025: < 0.1%● unchanged vs 02-2025
04-2025: < 0.1%● unchanged vs 03-2025
05-2025: 0.1%▲ +0.1 percentage points vs 04-2025
06-2025: 0.1%● unchanged vs 05-2025
07-2025: 0.1%● unchanged vs 06-2025
08-2025: 0.2%▲ +0.1 percentage points vs 07-2025highest value
09-2025: 0.1%▼ -0.1 percentage points vs 08-2025
10-2025: 0.1%● unchanged vs 09-2025
11-2025: 0.1%● unchanged vs 10-2025
12-2025: 0.1%● unchanged vs 11-2025
01-2026: 0.1%● unchanged vs 12-2025
02-2026: 0.1%● unchanged vs 01-2026
03-2026: 0.1%● unchanged vs 02-2026
04-2026: 0.1%● unchanged vs 03-2026
05-2026: 0.1%● unchanged vs 04-2026
06-2026: 0.1%● unchanged vs 05-2026
07-2026: 0.1%● unchanged vs 06-2026
08-2026: 0.1%● unchanged vs 07-2026
09-2026: 0.1%● unchanged vs 08-2026
10-2026: 0.1%● unchanged vs 09-2026
11-2026: 0.1%● unchanged vs 10-2026
Financial strengthAverage
Score breakdown
raises risk
1 change of registered office in 24 months
lowers risk
Sector: Human health activities (NACE 86)
Liquidity: current ratio 1.08, cash €43,895, halved
Size: total assets €60,670
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 12% of them on solvency, 20% on liquidity, 80% on profitability and 9% on growth.
The bankruptcy probability was computed on 05-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 2,153 companies had the same profile as Dr. Morgane Daix has now. Each dot stands for 6 companies, two years later.
96.1%
were still trading
2.2%
stopped another way
1.7%
went bankrupt
The bankruptcy probability of Dr. Morgane Daix itself is lower: 0.1% within 12 months. It rests on far more data about Dr. Morgane Daix than the profile alone.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 2,153 companies, not a prediction for Dr. Morgane Daix. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Weak solvency compared with the sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 11% of 20749 sector peers (2025).
NBB · sector comparisonPosition among 20749 sector peers
Solvency
better than 11%
← weakest
strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 25-06-2026, 36 days ahead of the deadline.
NBB · 5 filingsDeviation from the deadline
2025
36 days early
2024
8 days late
2023
26 days late
2022
20 days early
2021
23 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 5 accounts on average on the deadline day. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 8 August (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
06-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
Registered office moved from Liège to Neufchâteau
New registered office: Rue du Vicinal 3b, 4608 Neufchâteau · Previous registered office: Rue Laport 28, 4000 Liège · General meeting of 03-02-2025 · Gazette deed
Incorporation
Founder: Morgane Maguy Roger DAIX · Founding capital of €3,000, 1,000 shares · Appointment: Morgane Maguy Roger DAIX (director) · published on 04-05-2021 · Gazette deed
First establishment
Rue du Vicinal 3, Dalhem
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| Dr. Morgane Daix Dalhem | €60,670 | €47,643 | 6.4% | - |
| Dr Floriane Francis, médecine générale Villers-le-Bouillet | €62,041 | €50,159 | 3.2% | - |
| CABINET MEDICAL DR MAIRESSE SRL Braine-l'Alleud | €66,145 | €52,406 | 77.0% | - |
| Emmanuelle van Soest Huisarts Nijlen | €59,943 | €52,650 | 47.9% | - |
| Cabinet médical Dr Delphine Pirlet Oupeye | €63,235 | €41,763 | 33.5% | - |
| AD MEDIC Chaudfontaine | €66,478 | €50,128 | 49.0% | - |
| Dr. Neyens AE, huisarts Leuven | €64,451 | €52,322 | 7.8% | - |
These companies have the same main activity as Dr. Morgane Daix: general medical practice (NACE 86210). They are comparable in size and age: total assets between €59,900 and €66,500, founded between 2020 and 2022.
Official details
Source: KBO- Status
- Active since 30-04-2021Normal situation
- Activity
- General medical practiceNACE 86210
- Establishment unit
- 2.327.047.6184608 Dalhem, since 30-04-2021
- Financial year end
- 31 December
- Peppol
- Not found in the Peppol Directory
Annual accounts 2025
- ≈ €150,000estimated
- €60,670▼ 64.5%
- Filing
- Filed on 25-06-2026, 36 days before the end of the filing period
Insights on Dr. Morgane Daix
Dr. Morgane Daix files the micro format. That format states no turnover. The gross margin rose from €25,677 in 2021 to €47,643 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about Dr. Morgane Daix
- What is the company number of Dr. Morgane Daix?
- The company number of Dr. Morgane Daix is 0767.698.580. The VAT number is the same number with BE in front: BE 0767.698.580.
- Where is Dr. Morgane Daix based?
- The registered office is at Rue du Vicinal 3b, 4608 Dalhem.Company details
- What does Dr. Morgane Daix do?
- According to the KBO register, the main activity is general medical practice (NACE 86210).
- What is the legal form of Dr. Morgane Daix?
- Dr. Morgane Daix is a private limited company (BV).
- When was Dr. Morgane Daix founded?
- Dr. Morgane Daix was founded on 30-04-2021.
- Is Dr. Morgane Daix still active?
- Yes, Dr. Morgane Daix is an active enterprise in the KBO register.
- What is the turnover of Dr. Morgane Daix?
- The turnover in financial year 2025 is ≈ €150,000. This figure is estimated from the gross margin of €47,643 and 47 comparable companies (NACE 86). It probably lies between €110,000 and €210,000.Financials
- Is Dr. Morgane Daix profitable?
- In financial year 2025, Dr. Morgane Daix made a profit of €40,907.
- Where can I find the annual accounts of Dr. Morgane Daix?
- Dr. Morgane Daix filed 5 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Dr. Morgane Daix due?
- Dr. Morgane Daix must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.